The shares of a prominent pharma company gained up to 3 percent after the company announced plans to launch gTolvaptan (the generic version of Jynarque) in the US, which will generate a revenue opportunity of up to $150–200 million. Price Movement With a market...
Two pharmaceutical stocks witnessed strong gains following the impact of US tariffs and recent strategic acquisitions. Investor sentiment remained upbeat as these developments are expected to enhance market opportunities and strengthen business growth. The surge...
Pharma stock surged nearly 2 percent on Thursday morning following the announcement of receiving U.S. FDA approval for its new HIV drug. The approval paves the way for the company to market its generic version of a widely used HIV treatment, enhancing its position in...
The shares of this large-cap pharma stock engaged in the development and commercialization of a wide range of branded and generic formulations, API, and biotechnology products after the company reported a 72 percent year-on-year increase in net profits and revenue...
Search Topic or Keyword
Easiest Stock Screener Tool!
Best stock discovery tool with +130 filters, built for fundamental analysis. Profitability, Growth, Valuation, Liquidity, and many more filters. Search Stocks Industry-wise, Export Data For Offline Analysis, Customizable Filters.
